Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
139 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hyperlipidemia - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Hyperlipidemia - Pipeline Review, H1 2015', provides an overview of the Hyperlipidemia's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hyperlipidemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperlipidemia and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hyperlipidemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hyperlipidemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hyperlipidemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hyperlipidemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hyperlipidemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hyperlipidemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Hyperlipidemia Overview 11 Therapeutics Development 12 Pipeline Products for Hyperlipidemia - Overview 12 Pipeline Products for Hyperlipidemia - Comparative Analysis 13 Hyperlipidemia - Therapeutics under Development by Companies 14 Hyperlipidemia - Therapeutics under Investigation by Universities/Institutes 17 Hyperlipidemia - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Unknown Stage Products 21 Hyperlipidemia - Products under Development by Companies 22 Hyperlipidemia - Products under Investigation by Universities/Institutes 25 Hyperlipidemia - Companies Involved in Therapeutics Development 26 Ahn-Gook Pharmaceutical Co., Ltd. 26 Alnylam Pharmaceuticals, Inc. 27 Amgen Inc. 28 BCWorld Pharm Co. Ltd. 29 Catabasis Pharmaceuticals, Inc. 30 CJ CheilJedang Corp. 31 CrystalGenomics, Inc. 32 Daewoong Pharmaceutical Co., Ltd. 33 Eli Lilly and Company 34 Esperion Therapeutics, Inc. 35 HanAll Biopharma Co., Ltd. 36 Hanmi Pharmaceuticals, Co. Ltd. 37 Huons Co., Ltd. 38 Isis Pharmaceuticals, Inc. 39 Jeil Pharmaceutical Co., Ltd. 40 LG Life Sciences, Ltd. 41 Michigan Life Therapeutics, LLC 42 Pfizer Inc. 43 Pharmena SA 44 Piramal Enterprises Limited 45 Prometheon Pharma, LLC 46 Protalix BioTherapeutics, Inc. 47 Regeneron Pharmaceuticals, Inc. 48 TSH Biopharm Corporation Limited 49 Yuhan Corporation 50 Hyperlipidemia - Therapeutics Assessment 51 Assessment by Monotherapy Products 51 Assessment by Combination Products 52 Assessment by Target 53 Assessment by Mechanism of Action 55 Assessment by Route of Administration 57 Assessment by Molecule Type 59 Drug Profiles 61 (atorvastatin calcium + losartan potassium) - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 (atorvastatin calcium + metformin) - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 (gemigliptin + rosuvastatin calcium) - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 (rosuvastatin calcium + metformin SR) - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 (rosuvastatin calcium + telmisartan) - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 AGSAA-010 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 ALN-ANG - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Antisense Oligonucleotide to Inhibit Cide B for Hyperlipidemia and Atherosclerosis - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 BCWPC-001 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 bempedoic acid - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 bococizumab - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 BSN-272 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 CAT-2000 Series - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 CAT-2003 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 CG-301269 - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 CSN-501 - Drug Profile 77 Product Description 77 Mechanism of Action 77 R&D Progress 77 Drugs to Inhibit TRIP-Br2 for Metabolic Disorders - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 DWJ-1330 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 DWJ-1351 - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 etanercept biosimilar - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 evolocumab - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 gemcabene calcium - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 HCP-1007 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 HU-012 - Drug Profile 87 Product Description 87 Mechanism of Action 87 R&D Progress 87 ISIS-ANGPTL3Rx - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 JLP-1302 - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 JLP-1401 - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 LY-3015014 - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 microRNA-30c for Hyperlipidemia and Atherosclerosis - Drug Profile 92 Product Description 92 Mechanism of Action 92 R&D Progress 92 N-11 - Drug Profile 94 Product Description 94 Mechanism of Action 94 R&D Progress 94 P-7435 - Drug Profile 95 Product Description 95 Mechanism of Action 95 R&D Progress 95 PF-06427878 - Drug Profile 96 Product Description 96 Mechanism of Action 96 R&D Progress 96 Protein to Inhibit HMG-CoA Reductase for Hyperlipidemia - Drug Profile 97 Product Description 97 Mechanism of Action 97 R&D Progress 97 REGN-1001 - Drug Profile 98 Product Description 98 Mechanism of Action 98 R&D Progress 98 S-0101870 - Drug Profile 99 Product Description 99 Mechanism of Action 99 R&D Progress 99 Small Molecule for Hyperlipidemia - Drug Profile 100 Product Description 100 Mechanism of Action 100 R&D Progress 100 Small Molecule for Type 2 Diabetes and Hyperlipidemia - Drug Profile 101 Product Description 101 Mechanism of Action 101 R&D Progress 101 Synthetic Peptide for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile 102 Product Description 102 Mechanism of Action 102 R&D Progress 102 TRIA-662 - Drug Profile 104 Product Description 104 Mechanism of Action 104 R&D Progress 104 Hyperlipidemia - Recent Pipeline Updates 106 Hyperlipidemia - Dormant Projects 123 Hyperlipidemia - Discontinued Products 129 Hyperlipidemia - Product Development Milestones 130 Featured News & Press Releases 130 Nov 18, 2014: Amgen Presents Long-Term Data Showing Efficacy And Safety Of Investigational Cholesterol-Lowering Medication Evolocumab Across Lipid And LDL-C Levels 130 Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 132 Mar 19, 2014: Isis Pharmaceuticals Initiates Phase 1 Study of ISIS-ANGPTL3 Rx to Treat Hyperlipidemia 135 Mar 05, 2014: Esperion Therapeutics Provides ETC-1002 Program Update 135 Apr 13, 2012: HanAll BioPharma Initiates Phase I And III Trials Of HL040 136 Mar 19, 2010: FDA warns about increased risk of muscle injury with Zocor. 136 Mar 27, 2003: Zocor selected as sole high-potency HMG agent for U.S. Department of Veteran Affairs and Department of Defense. 136 Nov 05, 1998: Merck announces get-to-goal guarantee for patients taking cholesterol-lowering drug Zocor 136 Jul 05, 1995: FDA clears Merck's Zocor to save lives, prevent heart attacks; Zocor is first cholesterol-lowering drug available for this use 137 Appendix 138 Methodology 138 Coverage 138 Secondary Research 138 Primary Research 138 Expert Panel Validation 138 Contact Us 138 Disclaimer 139
List of Tables Number of Products under Development for Hyperlipidemia, H1 2015 12 Number of Products under Development for Hyperlipidemia - Comparative Analysis, H1 2015 13 Number of Products under Development by Companies, H1 2015 15 Number of Products under Development by Companies, H1 2015 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H1 2015 17 Comparative Analysis by Late Stage Development, H1 2015 18 Comparative Analysis by Clinical Stage Development, H1 2015 19 Comparative Analysis by Early Stage Development, H1 2015 20 Comparative Analysis by Unknown Stage Development, H1 2015 21 Products under Development by Companies, H1 2015 22 Products under Development by Companies, H1 2015 (Contd..1) 23 Products under Development by Companies, H1 2015 (Contd..2) 24 Products under Investigation by Universities/Institutes, H1 2015 25 Hyperlipidemia - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2015 26 Hyperlipidemia - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 27 Hyperlipidemia - Pipeline by Amgen Inc., H1 2015 28 Hyperlipidemia - Pipeline by BCWorld Pharm Co. Ltd., H1 2015 29 Hyperlipidemia - Pipeline by Catabasis Pharmaceuticals, Inc., H1 2015 30 Hyperlipidemia - Pipeline by CJ CheilJedang Corp., H1 2015 31 Hyperlipidemia - Pipeline by CrystalGenomics, Inc., H1 2015 32 Hyperlipidemia - Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 33 Hyperlipidemia - Pipeline by Eli Lilly and Company, H1 2015 34 Hyperlipidemia - Pipeline by Esperion Therapeutics, Inc., H1 2015 35 Hyperlipidemia - Pipeline by HanAll Biopharma Co., Ltd., H1 2015 36 Hyperlipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 37 Hyperlipidemia - Pipeline by Huons Co., Ltd., H1 2015 38 Hyperlipidemia - Pipeline by Isis Pharmaceuticals, Inc., H1 2015 39 Hyperlipidemia - Pipeline by Jeil Pharmaceutical Co., Ltd., H1 2015 40 Hyperlipidemia - Pipeline by LG Life Sciences, Ltd., H1 2015 41 Hyperlipidemia - Pipeline by Michigan Life Therapeutics, LLC, H1 2015 42 Hyperlipidemia - Pipeline by Pfizer Inc., H1 2015 43 Hyperlipidemia - Pipeline by Pharmena SA, H1 2015 44 Hyperlipidemia - Pipeline by Piramal Enterprises Limited, H1 2015 45 Hyperlipidemia - Pipeline by Prometheon Pharma, LLC, H1 2015 46 Hyperlipidemia - Pipeline by Protalix BioTherapeutics, Inc., H1 2015 47 Hyperlipidemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2015 48 Hyperlipidemia - Pipeline by TSH Biopharm Corporation Limited, H1 2015 49 Hyperlipidemia - Pipeline by Yuhan Corporation, H1 2015 50 Assessment by Monotherapy Products, H1 2015 51 Assessment by Combination Products, H1 2015 52 Number of Products by Stage and Target, H1 2015 54 Number of Products by Stage and Mechanism of Action, H1 2015 56 Number of Products by Stage and Route of Administration, H1 2015 58 Number of Products by Stage and Molecule Type, H1 2015 60 Hyperlipidemia Therapeutics - Recent Pipeline Updates, H1 2015 106 Hyperlipidemia - Dormant Projects, H1 2015 123 Hyperlipidemia - Dormant Projects (Contd..1), H1 2015 124 Hyperlipidemia - Dormant Projects (Contd..2), H1 2015 125 Hyperlipidemia - Dormant Projects (Contd..3), H1 2015 126 Hyperlipidemia - Dormant Projects (Contd..4), H1 2015 127 Hyperlipidemia - Dormant Projects (Contd..5), H1 2015 128 Hyperlipidemia - Discontinued Products, H1 2015 129
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
